CN103172692A - Medical raw material as well as preparation and application thereof - Google Patents
Medical raw material as well as preparation and application thereof Download PDFInfo
- Publication number
- CN103172692A CN103172692A CN2013101114772A CN201310111477A CN103172692A CN 103172692 A CN103172692 A CN 103172692A CN 2013101114772 A CN2013101114772 A CN 2013101114772A CN 201310111477 A CN201310111477 A CN 201310111477A CN 103172692 A CN103172692 A CN 103172692A
- Authority
- CN
- China
- Prior art keywords
- cyclovirobuxinum
- cyclovirobuxine
- raw material
- content
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and discloses a medical raw material as well as a preparation and an application thereof. The medical raw material comprises cyclovirobuxine D and cyclovirobuxine C. Through researches, people find that the content of cyclovirobuxine C in the raw material of cyclovirobuxine D is within a certain range, so that the hepatotoxicity of the raw material is remarkably reduced; and proved by pharmacodynamic tests, the raw material of cyclovirobuxine D disclosed by the invention has a favorable effect for treating angina, coronary disease and arrhythmia.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of medicine material and preparation and purposes of cyclovirobuxinum D.
Background technology
the Buxine preparation, it is the preparation for preparing take Buxaceae plant-little leaf boxwood as raw material, be the pioneering treatment cardiovascular and cerebrovascular diseases new drug of China, wherein Buxine Tablet is incorporated into " Chinese pharmacopoeia 2000 editions, 2005 editions, 2010 editions, said medicine belongs to traditional Chinese medicine, traditional Chinese medicine is in clinical application, treatment to disease has important effect, but traditional Chinese medicine is used as medicine mainly with compound medicinal material or compound extract, complicated component, unknown non-quantitation composition occupies significant proportion, exist impurity more, the curative effect material is unclear, the quality heterogeneity, unstable, and then cause clinical efficacy unstable, be difficult to search the problems such as reason after the generation untoward reaction, be difficult to adapt to the requirement of modernization and internationalization of Chinese herbal medicines.
Cyclovirobuxinum D system extracts the reactive monomer-alkaloid that obtains from Buxaceae plant little leaf boxwood and congener thereof, belong to derivatives of pregnane, molecular formula: C
26H
46N
20O, pharmacodynamic study show, cyclovirobuxinum D have obvious enhancing myocardial contraction effect, have diastole effect coronarius, have obvious function of resisting myocardial ischemia, have antiarrhythmic effect, have the provide protection to cerebral ischemia; Therefore, cyclovirobuxinum D is developed to new Chinese medicine significant.
Document " research of cyclovirobuxinum D hepatotoxicity mechanism ", (cyclovirobuxinum D is Effective Component of Chinese Medicine, obtains by extracting and purifying method to disclose the cyclovirobuxinum D raw material; According to art methods, all can not obtain absolute 100% material, it must contain certain impurity component) and by after oral administration, have certain liver toxicity, do not carry out deep research but form for the cyclovirobuxinum D raw material in the document.
Summary of the invention
For these reasons, the applicant finds by research, the content of Cyclovirobuxine C in the cyclovirobuxinum D raw material (Cyclovirobuxine C) within the specific limits, the liver toxicity of this raw material significantly reduces; Pharmacodynamics test shows, cyclovirobuxinum D of the present invention has the application in the medicines such as good treatment stenocardia, coronary heart disease, irregular pulse.
The present invention is achieved through the following technical solutions.
A kind of medicine material, medicine material comprise cyclovirobuxinum D and Cyclovirobuxine C, wherein the cyclovirobuxinum D weight content be greater than 95% tool less than 100%, the Cyclovirobuxine C weight content is greater than 0.2% and less than 5%.
Medicine material described above is preferably: the cyclovirobuxinum D weight content is more than or equal to 98.0% and less than 100%, and the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 2%.
Medicine material described above is preferably: the cyclovirobuxinum D weight content is more than or equal to 99.0% and less than 100%, and the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 1%.
Medicine material described above is preferably: the cyclovirobuxinum D weight content is more than or equal to 99.5% and less than 100%, and the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 0.5%.
The pharmaceutical preparation that any medicine material described above is prepared into.
The application of the described medicine material of above-mentioned any one in preparation treatment coronary heart diseases and angina pectoris medicine.
The application of the described medicine material of above-mentioned any one in preparation treatment antiarrhythmic medicament.
Pharmaceutical preparation described above comprises oral preparations and injection formulations.
Pharmaceutical preparation described above comprises tablet, capsule, aqueous injection, infusion solution or powder injection.
Aqueous injection described above consists of cyclovirobuxinum D raw material 1-3 weight part, tris-HCI buffer appropriate (transferring pH=5-6).
Wherein powder injection consists of cyclovirobuxinum D raw material 1-3 weight part, N.F,USP MANNITOL 40-60 weight part, tris-HCI buffer (transferring pH=5-6).
Annotate: in prior art, in Effective Component of Chinese Medicine, content more than or equal to 80%, namely is called this material, is all " cyclovirobuxinum D medicine material, its cyclovirobuxinum D content is more than or equal to 80% " such as " cyclovirobuxinum D " described in the prior art.
Following test is on the basis of test of many times, for technical scheme of the present invention, and the concluding test of carrying out.
One, liver toxicity test example
Test example 1
To Mouse Liver toxicity preliminary experiment
Trial drug:
1 group of trial drug: cyclovirobuxinum D content 92.1%, Cyclovirobuxine C content 7.8%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 81.7%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
2 groups of trial drugs: cyclovirobuxinum D content 94.9%, Cyclovirobuxine C content 4.9%, all the other are 0.2% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 83.9%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
3 groups of trial drugs: cyclovirobuxinum D content 96.3%, Cyclovirobuxine C content 3.6%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ g of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 84.7%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
4 groups of trial drugs: cyclovirobuxinum D content 99.0%, Cyclovirobuxine C content 0.8%, all the other are 0.2% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ g of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 87.3%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
5 groups of trial drugs: cyclovirobuxinum D content 99.5%, Cyclovirobuxine C content 0.4%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 88.2%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
6 groups of trial drugs: cyclovirobuxinum D content 99.7%, Cyclovirobuxine C content 0.2%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 88.9%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
Above-mentioned trial drug raw material 2g adds 2000ml water for injection before use, regulates pH value 5.5 with tris-HCI buffer, and is standby after sterilization.The blank group injects water, uses isopyknic tris-HCI buffer, mixes fully, and is standby.
Experimental animal: the KM mouse, male and female half and half, healthy of the right age, body weight 18-22g, Department Of Medicine, Peking University's Experimental Animal Center provides.
Test method: get mouse, male and female half and half, be divided at random blank group, trial drug group by body weight and sex, every group 10, the mouse tail vein administration, dosage is 0.035mg/kg, the blank group gives isopyknic water for injection, successive administration 3 days after 30 minutes, is got the centrifugal 10min of blood 3000r/min in the last administration, get serum, by the operation instructions of looking after mutually the test kit specification sheets, measure Serum ALT, AST with automatic biochemistry analyzer, measure ALB, ALP, TBI level with ultraviolet spectrophotometer.Get to cut open after blood and get mouse liver and weigh and calculate organ index.
Test-results: see Table 1 and table 2.
The impact of table 1 on the mice serum liver function indexes
Annotate: compare * * P＜0.01, * P＜0.05 with control group; Compare #P＜0.05 with 2 groups of tests.
Table 2 is dirty/body ratio test-results
Annotate: compare * * * P＜0.001, * * P＜0.01, * P＜0.05 with control group; Compare #P＜0.05 with 2 groups of tests.
Test 2
To the hepatotoxic proving test of mouse
1 group of trial drug: cyclovirobuxinum D content 95.1%, Cyclovirobuxine C content 4.8%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 84.1%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
2 groups of trial drugs: cyclovirobuxinum D content 99.2%, Cyclovirobuxine C content 0.6%, all the other are 0.2% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 87.4%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
3 groups of trial drugs: cyclovirobuxinum D content 99.4%, Cyclovirobuxine C content 0.5%, all the other are 0.1% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 87.9%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
4 groups of trial drugs: cyclovirobuxinum D content 99.9%, Cyclovirobuxine C content 0.05%, all the other are 0.05% years old.
The preparation method of above-mentioned cyclovirobuxinum D raw material is:
Preparative high performance liquid chromatography: moving phase is the 10mmol/L ammonium formiate: acetonitrile (8: 92), detect with light scattering detector.
Precision takes approximately the 10mg Control of Cyclovirobuxine D to the 25mL measuring bottle, add the dissolving of 5mL trichloromethane, again with dilution in acetonitrile to scale, as the Control of Cyclovirobuxine D mother liquor, this mother liquor is diluted to every 1mL successively with acetonitrile approximately contains the Control of Cyclovirobuxine D solution that cyclovirobuxinum D is 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision takes the approximately evergreen Chinese littleleaf box star C reference substance of 10mg ring, put in the 25mL measuring bottle, adding trichloromethane dissolves and is diluted to scale, as the ring evergreen Chinese littleleaf box star C reference substance mother liquor, with this mother liquor with acetonitrile be diluted to successively every 1mL approximately contain the ring evergreen Chinese littleleaf box star C be the evergreen Chinese littleleaf box star of the ring C reference substance solution of 1 μ g, 2 μ g, 5 μ g, 10 μ g and 20 μ g; Precision measures Control of Cyclovirobuxine D solution, each 20 μ L of the evergreen Chinese littleleaf box star C reference substance solution of ring respectively, and injecting chromatograph records retention time.
Sample preparation: get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 88.9%), add moving phase, dissolve complete, prepare the liquid phase post with the glycol-based bonded silica gel, according to retention time, intercepting cyclovirobuxinum D and the evergreen Chinese littleleaf box star C chromatographic peak solution of ring, concentrate drying, obtain trial drug raw material (wherein in the trial drug raw material, all the other for unknown impuritie, fubariticly go out concrete material).
Test method: the same.
Test-results: see Table 3 and table 4.
The impact of table 3 on the mice serum liver function indexes
Annotate: compare * * P＜0.01, * P＜0.05 with control group; Compare #P＜0.05 with 4 groups of tests.
Table 4 is dirty/body ratio test-results
Annotate: compare * * P＜0.01, * P＜0.05 with control group; Compare #P＜0.05 with 4 groups of tests.
Conclusion (of pressure testing): above-mentioned test shows, greater than 5% the time, produced liver toxicity when Cyclovirobuxine C content in the cyclovirobuxinum D raw material, and Cyclovirobuxine C content is less than 5% the time, and liver toxicity reduces; And when Cyclovirobuxine C content less than 0.2% the time, produced again liver toxicity, so determine the cyclovirobuxinum D medicine material: the cyclovirobuxinum D weight content is that the Cyclovirobuxine C weight content is greater than 0.2 and less than 5% greater than 95% and less than 100%; Be preferably: the cyclovirobuxinum D weight content is that the Cyclovirobuxine C weight content is greater than 1 and less than or equal to 2% more than or equal to 98.0% and less than 100%; Be preferably: the cyclovirobuxinum D weight content is that the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 1% more than or equal to 99.0% and less than 100%; Be preferably: the cyclovirobuxinum D weight content is that the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 0.5% more than or equal to 99.5% and less than 100%; Prove absolutely that in the cyclovirobuxinum D raw material, the control Cyclovirobuxine C is significant.
Annotate: above-mentioned trial drug group also can prepare by the following method:
Get and contain cyclovirobuxinum D medicine material (cyclovirobuxinum D content is 84.7%), add purified water 30L, stirring suspension drips strong aqua and regulates pH value to 8～9, drips the ammoniacal liquor process and keeps system temperature to be no more than 50 ℃.Add again chloroform extraction 3 times, merge organic layer.Add again 0.2mol/L Na
2HPO
4-0.2mol/L tartaric acid buffer (pH7.0) stirs separatory.Abandon organic layer, get upper aqueous layer set to 0～4 ℃ of conditions under refrigeration crystallization 24 hours.Filter, filter cake does not need drying, directly enters next step.
Get above-mentioned crystallization filter cake, add purified water, stirring suspension, (this step can be followed the trail of with high-efficient liquid phase technique to 9.5-11.5 to drip strong aqua adjusting pH value, determine the content of Cyclovirobuxine C, thereby adjust the pH value), drip the ammoniacal liquor process and keep system temperature to be no more than 45 ℃.Add again chloroform extraction 3 times, merge organic layer.Add anhydrous sodium sulphate, drying is filtered, and filtrate removes solvent under reduced pressure below 60 ℃, gets white solid (according to the above-mentioned method that the prepares liquid phase sample of testing, obtaining different tests medicine group sample).
Annotate: the preparation method of cyclovirobuxinum D medicine material of the present invention, can also adopt silica gel column chromatography method to obtain.
Annotate: cyclovirobuxinum D medicine material described above (cyclovirobuxinum D content greater than 80% less than 90%) is all available from Chengdu Rui Fensi bio tech ltd.
Two, pharmacological test example
Provide protection to the anesthetized rat myocardial ischemia-reperfusion injury
Laboratory animal: healthy SD rat, body weight 240-260g.
Trial drug:
1 group of trial drug: cyclovirobuxinum D content 99.5%, Cyclovirobuxine C content 0.4%, all the other are 0.1% years old.
Above-mentioned test trial drug group raw material 2g adds 2000ml water for injection before use, regulates pH value 5.5 with tris-HCI buffer, and is standby after sterilization.The blank group injects water, uses isopyknic tris-HCI buffer, mixes fully, and is standby.
Test reagent: 20% urethane is pressed; The tincture of iodine; Test kit; 1%TTC.
Test apparatus: respirator; Electrocardiograph; Ophthalmic tweezers; Automatic clinical chemistry analyzer; Digital camera.
Test method: with the rat random packet: blank group, trial drug group.Be placed in the pre-raising of equivalent environment 2 days, free diet.After pre-raising finishes, test, animal is weighed, and 20% urethane is pressed the 0.6ml/100g abdominal injection, after anesthesia is satisfied, to lie on the back and be fixed on the mouse plate, trachea cannula connects respirator, by 10～12ml Tidal volume, the frequency of 70 times/minutes is exhaled, and continuous positive pressure breathing is inhaled: exhale than being 1: 1.Adjust respiration parameter according to respiratory rate and the degree of depth.Connect subsequently electrocardiograph, survey normal ECG.cut off front field of operation hair, iodine disinfection, cut off skin, subcutis, front muscle and manadesma 3～4cm, long along the 3rd intercostal blunt separation intercostal muscle 3cm with the 18# vascular clamp, open thoracic cavity and pericardium, recording ecg, strut 3, 4 ribs, hold Rat Right pleurobranch chamber with left hand four fingers, the assistant upwards pushes away thymus gland with ophthalmic tweezers, find ligation sign blood vessel great cardiac vein between left auricle of heart and pulmonary conus, 2mm creates roundlet pin band 6-0 silk thread threading with nothing in the place below left auricle of heart, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg after threading, through the tail intravenously administrable, dosage is 0.2mg/kg, recording ecg after administration 10min, and with one with the little plastics pipe pad of groove at the ligation position, the ligation thereon of two rear line heads.At once recording ecg after ligation is cyanosis or the II S-T section back of a bow that leads take left chamber antetheca and upwards raises greater than 0.1mv and more than lasting 0.5h and successfully indicate (the S-T section is superseded without the changer) for ligation.After ligation, 10min recording ecg again, cut off ligature after ligation 30min, realizes perfusion again, and record pours into electrocardiogram(ECG at once again, removes in the thoracic cavity layer-by-layer suture wall of the chest after hematocele, removes respirator, animal recovery autonomous respiration, and incision of trachea does not process.Fill with again at once, 10min, 20min, 40min, 1h, 2h, 3h recording ecg respectively.Heart after refrigerator and cooled is frozen 10min, is cut into left chamber from the apex of the heart parallel coronary sulcus direction in the centripetal end 5 of equal thickness, puts into 1% TTC dye liquor, 37 ℃ of dyeing 10min, the necrotic area is not garnet, the necrotic area is canescence.Digital camera is taken pictures.Weighed respectively in necrotic area and non-necrotic area, calculate the per-cent that the necrotic area accounts for left ventricular mass, i.e. infarction size.
Test-results: the results are shown in Table 5.
The impact of table 5 on the rat myocardial infarction model scope
Annotate: compare * P＜0.05, * * P＜0.01 with the blank group.
Test 2
Calcium chloride is brought out the impact of rat ventricular
Trial drug:
1 group of trial drug: cyclovirobuxinum D content 99.5%, Cyclovirobuxine C content 0.4%, all the other are 0.1% years old.
Above-mentioned test trial drug group raw material 2g adds 2000ml water for injection before use, regulates pH value 5.5 with tris-HCI buffer, and is standby after sterilization.The blank group injects water, uses isopyknic tris-HCI buffer, mixes fully, and is standby.
Experimental technique: the Wistar rat is divided into group at random: control group, trial drug group group.20% urethane is after intraperitoneal injection of anesthesia (1.2mg/kg), and dorsal position is fixed, and it is subcutaneous that needle electrode inserts animal foot, record standard limbs II lead electrocardiogram.If electrocardiogram(ECG has ischemic or other Novel presentation, reject from this experiment.The tail vein is the tested medicine 0.2mg/kg of injection slowly, and control group waits capacity physiological saline, after administration 10min, in 10s through complete 2% calcium chloride of tail intravenous injection (140mg/kg), irregular pulse time of occurrence, time length after the observation administration.
Experimental result: the results are shown in Table 6.
Table 6 brings out the impact of rat ventricular on calcium chloride
Annotate: compare * P＜0.05, * * P＜0.01 with control group.
Conclusion (of pressure testing): above-mentioned test shows, medicine material of the present invention has good treatment coronary heart diseases and angina pectoris, ARR pharmacological action.
Preparation Example
Embodiment 1
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 95.7%, the Cyclovirobuxine C weight content is 3.9%, all the other impurity 0.4%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 1g, water for injection 1000ml, tris-HCI buffer appropriate (adjust pH=5.0); Perhaps cyclovirobuxinum D raw material 1g, water for injection 1000ml, citric acid appropriate (adjust pH=5.0).
Wherein powder injection forms: cyclovirobuxinum D raw material 1g, water for injection 1000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.0); Perhaps cyclovirobuxinum D raw material 1g, N.F,USP MANNITOL 50g, water for injection 1000ml, citric acid appropriate (adjust pH=5.0)
Embodiment 2
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 99.1%, the Cyclovirobuxine C weight content is 0.7%, all the other impurity 0.2%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 2g, water for injection 2000ml, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Wherein powder injection forms: cyclovirobuxinum D raw material 2g, water for injection 2000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, N.F,USP MANNITOL 50g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5)
Embodiment 3
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 99.3%, the Cyclovirobuxine C weight content is 0.5%, all the other impurity 0.2%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 2g, water for injection 2000ml, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Wherein powder injection forms: cyclovirobuxinum D raw material 2g, water for injection 2000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, N.F,USP MANNITOL 50g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5)
Embodiment 4
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 99.6%, the Cyclovirobuxine C weight content is 0.3%, all the other impurity 0.1%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 2g, water for injection 2000ml, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Wherein powder injection forms: cyclovirobuxinum D raw material 2g, water for injection 2000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, N.F,USP MANNITOL 50g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Embodiment 5
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 99.1%, the Cyclovirobuxine C weight content is 0.8%, all the other impurity 0.1%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 2g, water for injection 2000ml, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Wherein powder injection forms: cyclovirobuxinum D raw material 2g, water for injection 2000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, N.F,USP MANNITOL 100g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Embodiment 6
A kind of medicine material, wherein the cyclovirobuxinum D weight content is 99.5%, the Cyclovirobuxine C weight content is 0.4%, all the other impurity 0.1%.
Above-mentioned raw materials is prepared into aqueous injection, infusion solution, powder injection, tablet, capsule etc.
Wherein aqueous injection consists of: cyclovirobuxinum D raw material 2g, water for injection 2000ml, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Wherein powder injection forms: cyclovirobuxinum D raw material 2g, water for injection 2000ml, N.F,USP MANNITOL 50g, tris-HCI buffer appropriate (adjust pH=5.5); Perhaps cyclovirobuxinum D raw material 2g, N.F,USP MANNITOL 50g, water for injection 2000ml, citric acid appropriate (adjust pH=5.5).
Preparation Example includes but not limited to above-mentioned.
Claims (10)
1. a medicine material, is characterized in that medicine material comprises cyclovirobuxinum D and Cyclovirobuxine C.
2. a kind of medicine material according to claim 1, wherein the cyclovirobuxinum D weight content is greater than 95% and less than 100%, the Cyclovirobuxine C weight content is greater than 0.2% and less than 5%.
3. a kind of medicine material according to claim 1, wherein the cyclovirobuxinum D weight content is more than or equal to 98.0% and less than 100%, the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 2%; Perhaps the cyclovirobuxinum D weight content is more than or equal to 99.0% and less than 100%, and the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 1%.
4. a kind of medicine material according to claim 1, wherein the cyclovirobuxinum D weight content is more than or equal to 99.5% and less than 100%, the Cyclovirobuxine C weight content is greater than 0.2% and less than or equal to 0.5%.
5. the pharmaceutical preparation that is prepared into of the described a kind of medicine material of according to claim 1-4 any one.
6. the application of according to claim 1-4 described medicine materials of any one in preparation treatment coronary heart diseases and angina pectoris medicine.
7. the application of according to claim 1-4 described medicine materials of any one in preparation treatment antiarrhythmic medicament.
8. the pharmaceutical preparation that is prepared into of a kind of medicine material according to claim 5, wherein pharmaceutical preparation comprises oral preparations and injection formulations.
9. the pharmaceutical preparation that is prepared into of a kind of medicine material according to claim 5, wherein pharmaceutical preparation comprises tablet, capsule, aqueous injection, infusion solution or powder injection.
10. the pharmaceutical preparation that is prepared into of a kind of medicine material according to claim 8, wherein aqueous injection consists of cyclovirobuxinum D raw material 1-3 weight part, tris-HCI buffer; Wherein powder injection consists of cyclovirobuxinum D raw material 1-3 weight part, N.F,USP MANNITOL 40-60 weight part, tris-HCI buffer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310111477.2A CN103172692B (en) | 2013-04-02 | 2013-04-02 | A kind of medicine material and preparation and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310111477.2A CN103172692B (en) | 2013-04-02 | 2013-04-02 | A kind of medicine material and preparation and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103172692A true CN103172692A (en) | 2013-06-26 |
| CN103172692B CN103172692B (en) | 2016-05-25 |
Family
ID=48632942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310111477.2A Active CN103172692B (en) | 2013-04-02 | 2013-04-02 | A kind of medicine material and preparation and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103172692B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814616A (en) * | 2006-03-13 | 2006-08-09 | 杭太俊 | Buxine, buxine hydrochloride, and its preparing method and formulation |
-
2013
- 2013-04-02 CN CN201310111477.2A patent/CN103172692B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814616A (en) * | 2006-03-13 | 2006-08-09 | 杭太俊 | Buxine, buxine hydrochloride, and its preparing method and formulation |
Non-Patent Citations (1)
| Title |
|---|
| 刘洁等: "黄杨宁原料中生物碱的分离与鉴定", 《中草药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103172692B (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9243019B2 (en) | Hydroxysafflor yellow A sodium and preparation as well as application thereof | |
| CN100490795C (en) | Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof | |
| CN100569219C (en) | A kind of pharmaceutical composition that is used for oral formulations and preparation method thereof | |
| CN1689575B (en) | Application of ocotillol in the preparing process of medicine for treating or preventing cardiovascular and cerebrovascular disease | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN101006984B (en) | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN100496527C (en) | Preparation method and application of injection containing Erigeron breviscapus | |
| CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN101518509A (en) | Oral drug combination containing salvianolic acid A | |
| CN101759672A (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101006975B (en) | An oral medicine preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN103172691A (en) | Medical raw material as well as preparation and application thereof | |
| CN103172692A (en) | Medical raw material as well as preparation and application thereof | |
| CN103919759B (en) | A kind of containing danshensu sodium, the pharmaceutical composition of salvia miltiorrhiza tanshinoate F and preparation thereof | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN101152285A (en) | Pharmaceutical composition of snakegourd fruit and whitethorn leaf | |
| CN1931216B (en) | Medicine composition of safflower and rhodiola root | |
| EP2899186B1 (en) | New hydroxysafflor yellow pharmaceutical salts | |
| CN101019878B (en) | Injection medicine composite containing salvianolic acid A and its preparation | |
| CN103191131B (en) | Traditional Chinese medicine raw material as well as preparation and use thereof | |
| CN101019824B (en) | Preparation method of oral medicine composition containing salvianolic acid | |
| CN103191130B (en) | Traditional Chinese medicine raw material as well as preparation and use thereof | |
| CN104173358A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104435105B (en) | One kind is by Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, the pharmaceutical composition of dalbergia wood preparation | |
| CN102988399A (en) | Medicine composition and application and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building C-4-15A Applicant after: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building B block 22 layer Applicant before: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. |
|
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Lin Qionggang 850000 Lhasa Road, Tibet autonomous region economic and Technological Development Zone Applicant after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 100098 Beijing city Haidian District No. 48 Zhichun Road Yingdu building C-4-15A Applicant before: Tibet Yiming Xiya Biological Medical Technology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIBET YIMING XIYA BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. TO: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: Lin Qionggang road Lhasa 850000 Tibet autonomous region economic and Technological Development Zone No. 6 Patentee after: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: Lin Qionggang 850000 Lhasa Road, Tibet autonomous region economic and Technological Development Zone Patentee before: XIZANG YIMING XIYA PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
| CP02 | Change in the address of a patent holder |